Hospitals are increasingly investing in modernizing their food-service systems. Shore Medical Center says the technology is a factor in a 10% improvement in its Press Ganey patient-satisfaction scores and credits the system with saving about $25,000 yearly because of less food waste.
Mylan CEO Heather Bresch's recent announcement that Mylan is looking to extend the shelf life of the EpiPen could be a relief for patients, but a costly move for Mylan since it may take significant research and development to change epinephrine, the drug inside the EpiPen.
In the three years since the FDA published final regulations on a unique device identifier system, most manufacturers and distributors have successfully started phasing in UDIs for their products. But few healthcare providers are able to take full advantage of the data.
Patient satisfaction isn't just about the way patients are treated by physicians and staff. The equipment and products used in healthcare facilities can have a significant impact on patient opinion, according to an industry report.
Pharmacists are concerned that several forms of penicillin are in shortage, including one used as the primary treatment for syphilis.
Operating rooms produce on average more than 2,000 tons of waste per day, and a significant portion of that waste is from disposable medical supplies. A recent study found that on average $968 worth of disposable medical supplies in the operating room are wasted per procedure.
Following pressure from distributors, the Food and Drug Administration announced Wednesday that it would extend a deadline for firms to comply with new labeling guidelines for prepackaged kits and repackaged single-use devices.
Practice Greenhealth has made yet another move into supply chain with the expected launch of a tool that helps hospitals forecast the total cost of using and maintaining a product, beyond just the purchase price.
Mylan made a somewhat surprising announcement Monday that it would launch a generic version of its EpiPen in several weeks and sell it for half the list price of its branded product. So where have those plans been for the decade it's been selling the product?
Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients without insurance or with high-deductible coverage.
The controversy surrounding Mylan's EpiPen pricing suggests drugmakers have been slow to adapt to an environment in which millions of Americans must pay thousands of dollars out of pocket before their coverage kicks in.
Healthcare group purchasing and services company Premier reported a slight decrease in fourth-quarter profit due to severance-related costs in its data software and consulting division.